• MannKind swung to a third-quarter 2026 net loss of $23.22 million from a year-earlier profit.
• Total revenue rose 24% year over year to $101.87 million, primarily due to the Furoscix acquisition and higher royalties.
• Commercial product revenue more than doubled year over year to $45 million.
• Furoscix ReadyFlow shipments began in mid-September, reaching approximately 75% of Furoscix shipments by late October.
• Chief Executive Michael Castagna expects fourth-quarter Furoscix revenue to exceed its first-half 2026 total.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MannKind Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611051601PRIMZONEFULLFEED9871730) on November 05, 2026, and is solely responsible for the information contained therein.